| P50 | author | Sanjiv Mahadeva | Q40573709 |
| P2093 | author name string | Siew Siang Chua | |
| | Hooi Leng Lee | |
| P2860 | cites work | Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Ag | Q46317678 |
| | Use of physician education and computer alert to improve targeted use of gastroprotection among NSAID users. | Q46598049 |
| | Utilisation of non-steroidal anti-inflammatory drugs (NSAIDs) through community pharmacies in Malaysia | Q46903259 |
| | Association of nonsteroidal anti-inflammatory drugs with first occurrence of heart failure and with relapsing heart failure: the Rotterdam Study | Q77583006 |
| | Adherence to gastroprotection and the risk of NSAID-related upper gastrointestinal ulcers and haemorrhage | Q80530472 |
| | National adherence to evidence-based guidelines for the prescription of nonsteroidal anti-inflammatory drugs | Q81361980 |
| | Are traditional NSAIDs prescribed appropriately among French elderly with osteoarthritis? Results from the CADEUS cohort | Q83568008 |
| | Assessment of gastrointestinal and cardiovascular risk in patients with osteoarthritis who require NSAIDs: the LOGICA study | Q84291412 |
| | Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials | Q24619410 |
| | Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach | Q24673561 |
| | Nonsteroidal anti-inflammatory drugs, gastroprotection, and benefit-risk | Q26864640 |
| | Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials | Q28193800 |
| | Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategies | Q28200569 |
| | Guidelines for prevention of NSAID-related ulcer complications | Q33412100 |
| | Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s | Q33974678 |
| | Nonsteroidal anti-inflammatory drug-associated dyspepsia: the scale of the problem | Q34134268 |
| | Epidemiology and pharmacoeconomic implications of non-steroidal anti-inflammatory drug-associated gastrointestinal toxicity | Q34200679 |
| | Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage | Q34387174 |
| | Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis | Q34520598 |
| | Understanding the NSAID related risk of vascular events | Q34546560 |
| | Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial | Q34720605 |
| | Prescription of and adherence to non-steroidal anti-inflammatory drugs and gastroprotective agents in at-risk gastrointestinal patients | Q36011124 |
| | Adherence to the preventive strategies for nonsteroidal anti-inflammatory drug- or low-dose aspirin-induced gastrointestinal injuries | Q36844540 |
| | Nonsteroidal anti-inflammatory drugs: adverse effects and their prevention | Q37281673 |
| | The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel. | Q37787639 |
| | Adherence to gastroprotection during cyclooxygenase 2 inhibitor treatment and the risk of upper gastrointestinal tract events: a population-based study | Q38433161 |
| | Suboptimal gastroprotective coverage of NSAID use and the risk of upper gastrointestinal bleeding and ulcers: an observational study using three European databases | Q38438448 |
| | Nonsteroidal Anti-Inflammatory Drug-Induced Gastroduodenal Bleeding: Risk Factors and Prevention Strategies | Q38974392 |
| | Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study | Q41019717 |
| | Time-trends in gastroprotection with nonsteroidal anti-inflammatory drugs (NSAIDs). | Q43133431 |
| | Underutilization of gastroprotective drugs in patients receiving non-steroidal anti-inflammatory drugs | Q44097676 |
| | Adherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs | Q44678732 |
| | Prescription rates of protective co-therapy for NSAID users at high GI risk and results of attempts to improve adherence to guidelines | Q44950755 |
| | Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks | Q46215825 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P304 | page(s) | 1649-1657 | |
| P577 | publication date | 2016-11-10 | |
| P1433 | published in | Therapeutics and Clinical Risk Management | Q15766913 |
| P1476 | title | Utilization of gastroprotective strategies for nonsteroidal anti-inflammatory drug-induced gastrointestinal events in a major teaching hospital | |
| P478 | volume | 12 | |